Rapport Therapeutics, Inc. (RAPP)
(Delayed Data from NSDQ)
$14.61 USD
+0.18 (1.25%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $14.64 +0.03 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Rapport Therapeutics, Inc.'s return on equity, or ROE, is -25.48% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that RAPP has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
RAPP 14.61 +0.18(1.25%)
Will RAPP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RAPP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for RAPP
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
RAPP: HC Wainwright & Co. Initiates Coverage with a "Buy" Rating | RAPP Stock News
Rapport Therapeutics initiated with bullish view at H.C. Wainwright, here's why
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Citizens JMP